Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328614 · ClinicalTrials.gov registry record · Phase 1
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00328614 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 32 participants.
The verdict
NCT00328614, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
Interventions
- DEVICE Radiation Therapy
- DRUG Samarium-153
- DRUG Total Androgen Suppression (TAS) with Bicalutamide
- DRUG Total androgen suppression (TAS) with Goserelin Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00328614
The ClinicalTrials.gov registry entry for NCT00328614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT00328614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00328614 about?
NCT00328614 is a clinical study titled "Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer". The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
What is the current status of trial NCT00328614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2003-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00328614?
The interventions under investigation include: Radiation Therapy (DEVICE), Samarium-153 (DRUG), Total Androgen Suppression (TAS) with Bicalutamide (DRUG), Total androgen suppression (TAS) with Goserelin Acetate (DRUG).
Who is sponsoring clinical trial NCT00328614?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.